What do the trials say about cagrilintide dosage?

Every vial at a glance.

Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
Vial1 mL of water2 mL of water
5 mg5 mg/mL: 0.6 mg is 12 units, 1.2 mg is 24 units, 2.4 mg is 48 units2.5 mg/mL: 0.6 mg is 24 units, 1.2 mg is 48 units, 2.4 mg is 96 units
10 mg10 mg/mL: 0.6 mg is 6 units, 1.2 mg is 12 units, 2.4 mg is 24 units5 mg/mL: 0.6 mg is 12 units, 1.2 mg is 24 units, 2.4 mg is 48 units

Jump to a vial 5 mg 10 mg

In the 26-week phase 2 dose-finding trial by Lau and colleagues (2021), 706 adults without diabetes were enrolled1 and randomly assigned to once-weekly cagrilintide at 0.3, 0.6, 1.2, 2.4 or 4.5 mg, once-daily liraglutide 3.0 mg or placebo, with a dose escalation of up to 6 weeks.2

Doses in the cagrilintide trials

The vial table is arithmetic only: neither the sources nor the logged rows give a cagrilintide vial, and the doses are ones the trials gave. No cagrilintide label, regulator dosing document or labelled strength turned up in the searches, so every dose here is one a trial gave.

TrialDose and schedulePeopleLength
Lau et al. 2021, phase 2 dose-finding2Once-weekly cagrilintide 0.3, 0.6, 1.2, 2.4 or 4.5 mg, against once-daily liraglutide 3.0 mg or placebo706 adults without diabetes enrolled126 weeks, including escalation of up to 6 weeks
Enebo et al. 2021, phase 1b, with semaglutide3Once-weekly cagrilintide 0.16, 0.30, 0.60, 1.2, 2.4 or 4.5 mg, or placebo, each with once-weekly semaglutide 2.4 mg96 randomised, aged 18-55 and otherwise healthy, 24 on placebo16 weeks escalation, 4 weeks at target, 5 weeks follow-up
Frias et al. 2023, phase 2 in type 2 diabetes4Once-weekly cagrilintide alone, against CagriSema or semaglutide, all escalated to 2.4 mg92 randomised, 30 on cagrilintide32 weeks
REDEFINE 1, Garvey et al. 202556Once-weekly cagrilintide 2.4 mg alone or with semaglutide 2.4 mg, against semaglutide 2.4 mg alone or placebo3417 adults without diabetes randomised, 302 on cagrilintide alone68 weeks, including 16 weeks of escalation
REDEFINE 2, Davies et al. 20257Once-weekly cagrilintide-semaglutide (2.4 mg each), against placebo1206 adults with type 2 diabetes randomised, 904 on the combination68 weeks

Is there a label or a labelled strength?

Searches of DailyMed, ClinicalTrials.gov and PubMed returned no cagrilintide label, regulator dosing document or labelled strength. In its release, Novo Nordisk says it submitted CagriSema, cagrilintide 2.4 mg with semaglutide 2.4 mg, to the FDA as a once-weekly injection for adults with obesity.8 The maker's release also says CagriSema is not approved.8

No Milligram figure for cagrilintide is printed, because none was usable at the reporting floor.

How the doses were stepped up

In the phase 2 registry results, the 2.4 mg arm received 0.6 mg at week 0, 1.2 mg at week 2, then 2.4 mg from week 4 to week 26.1 The 4.5 mg arm received 0.6 mg at week 0, 1.2 mg at week 2 and 2.4 mg at week 4, then 4.5 mg from week 6 to week 26.1

The phase 1b trial by Enebo et al. (2021), in 96 people, co-escalated cagrilintide and semaglutide 2.4 mg in 4-week intervals to the target dose over 16 weeks, then gave the target dose for 4 weeks.3 The REDEFINE 1 registry entry (NCT05567796) gives a 16-week dose escalation before 52 weeks of maintenance in both the combination arm and the cagrilintide-alone arm, and the mg per step is not in the saved text.6 The authors of the single-dose kidney and liver impairment studies say they chose 0.6 and 0.9 mg, lower than the 2.4 mg dose in clinical development, because higher doses may be associated with gastrointestinal adverse effects, in particular nausea and vomiting, and require dose escalation to be attained.9

Route and injection site

The phase 2 trial gave cagrilintide as once-weekly subcutaneous self-injections, using a NovoPen 4 pen-injector.21 The phase 2 registry entry says the injection went into a skin fold in the stomach, thigh or upper arm.1 The phase 1b registry entry places the injection in a lifted fold of abdominal skin, and in the kidney and liver impairment studies qualified site staff gave a single 0.6 mg or 0.9 mg dose in an abdominal skinfold with a NovoPen 4.109

Mixing, concentration and storage

The phase 2 trial and the kidney and liver impairment studies gave cagrilintide with a NovoPen 4 pen-injector,19 and the sources searched give no powder, water volume, pH, mg per mL concentration or storage condition for the product. With no sourced vial strength and no logged vial, the vial table is arithmetic only, and no worked syringe example or preset calculator default is shown.

The mixing guide covers the general steps, and the cagrilintide calculator works a sum from any vial strength entered.

Combining cagrilintide with tirzepatide or retatrutide

Searches of the trial registry and PubMed found no human trial of cagrilintide combined with retatrutide or tirzepatide. The registry lists three phase 3 trials that compare CagriSema with tirzepatide (NCT06221969, NCT06131437 and NCT06534411) rather than combine them, and the only PubMed result with retatrutide is a study in rats. The dosing of each partner drug is in the semaglutide, tirzepatide and retatrutide guides, and the class is in GLP-1 and incretin. More on cagrilintide itself is on its compound page.

References

  1. ClinicalTrials.gov. NCT03856047: Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. 2023. clinicaltrials.gov
  2. PubMed. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. 2021. pubmed.ncbi.nlm.nih.gov
  3. PubMed. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. 2021. pubmed.ncbi.nlm.nih.gov
  4. PubMed. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. 2023. pubmed.ncbi.nlm.nih.gov
  5. PubMed. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. 2025. pubmed.ncbi.nlm.nih.gov
  6. ClinicalTrials.gov. NCT05567796: A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight. 2026. clinicaltrials.gov
  7. PubMed. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. 2025. pubmed.ncbi.nlm.nih.gov
  8. Novo Nordisk (BioSpace). Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management. biospace.com
  9. PMC. Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. 2026. pmc.ncbi.nlm.nih.gov
  10. ClinicalTrials.gov. NCT03600480: A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese. 2020. clinicaltrials.gov